Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.APHB · Entity 6329 | Director · Chief Executive Officer | December 08, 2017 | December 12, 2017 |
| Inhibikase Therapeutics, Inc.IKT · Entity 5838 | Director | July 16, 2024 | July 18, 2024 |
| Regulus Therapeutics Inc.RGLS · Entity 78034 | Director · President & CEO | February 15, 2017 | February 23, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date December 08, 2017 · Filed December 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 599 |
Reported balance
After 2017-12-08 transaction · row 1
1 source rowRow 1 · 2017-12-08 · Grant · Acquired 599 · Balance 599 F1: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Inhibikase Therapeutics, Inc.
Report date July 16, 2024 · Filed July 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.54 · Expires 2031-07-16 | Direct | 30,000 |
Reported balance
After 2024-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-16 · Grant · Acquired 30,000 · Balance 30,000 F1: The options will vest on the earlier of July 16, 2025 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest on the earlier of July 16, 2025 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
Regulus Therapeutics Inc.
Report date February 15, 2017 · Filed February 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2027-02-14 | Direct | 410,000 |
Reported balance
After 2017-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-15 · Grant · Acquired 410,000 · Balance 410,000 F1: 25% of the shares vest on January 1, 2018 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on January 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares vest on January 1, 2018 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on January 1, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2024 Filed Jul 18, 2024 21:27 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000950170-24-084674 · ownership.xml · derivative · entry 1 GRINT PAUL C · CIK 0001236548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-07-16 F1 · derivative.exercise_date: The options will vest on the earlier of July 16, 2025 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 01:12 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 6,667 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000950170-23-031852 · ownership.xml · derivative · entry 1 GRINT PAUL C · CIK 0001236548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2033-06-30 F1 · derivative.exercise_date: The options will vest on the earlier of June 30, 2024 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. Read SEC document |
| June 24, 2022 Filed Jun 29, 2022 01:00 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001209191-22-039710 · doc4.xml · derivative · entry 1 GRINT PAUL C · CIK 0001236548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-06-24 F1 · derivative.exercise_date: This entire stock option grant will vest 100% in a single tranche on the earlier of June 24, 2023 or the day prior to the next annual meeting of stockholders. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 23:11 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 22,677 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-21-086990 · tm2120992d3_4.xml · derivative · entry 1 GRINT PAUL C · CIK 0001236548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,677 Underlying: Common Stock · 22,677 shares Expires 2028-06-25 Read SEC document |
| December 22, 2020 Filed Dec 30, 2020 02:53 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 6,825 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-20-140310 · tm2039455d4_form4.xml · derivative · entry 1 GRINT PAUL C · CIK 0001236548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,825 Underlying: Common Stock · 6,825 shares Expires 2030-12-22 Read SEC document |
| December 08, 2017 Filed Dec 12, 2017 23:14 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | GrantCommon Stock | 599 | $0.62 | $371.38 |
DisclosureSEC source: 0001209191-17-065259 · doc4.xml · nonDerivative · entry 1 GRINT PAUL C · CIK 0001236548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599 F1 · timeliness: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 07, 2017 Filed Sep 12, 2017 00:17 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 285,113 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001209191-17-052308 · doc4.xml · derivative · entry 2 GRINT PAUL C · CIK 0001236548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,113 Underlying: Common Stock · 285,113 shares Expires 2027-09-06 F2 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest and become exercisable on September 5, 2027, subject to earlier vesting upon the satisfaction of performance criteria. Read SEC document |
| September 07, 2017 Filed Sep 12, 2017 00:17 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 190,076 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001209191-17-052308 · doc4.xml · derivative · entry 1 GRINT PAUL C · CIK 0001236548 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,076 Underlying: Common Stock · 190,076 shares Expires 2027-09-06 F1 · derivative.exercise_date: 1/4th of the shares subject to the option vest on September 7, 2018. The remainder of the shares vest in equal monthly installments thereafter over the next three years. Read SEC document |
| February 15, 2017 Filed Feb 23, 2017 17:21 UTC | Regulus Therapeutics Inc. RGLS · Entity 78034 | GrantStock Option (Right to Buy) · Derivative | 410,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-17-013896 · doc4.xml · derivative · entry 1 GRINT PAUL C · CIK 0001236548 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: 25% of the shares vest on January 1, 2018 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on January 1, 2021. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 17:10 UTC | Regulus Therapeutics Inc. RGLS · Entity 78034 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001209191-17-006791 · doc4.xml · derivative · entry 1 GRINT PAUL C · CIK 0001236548 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2026-02-03 F1 · balance_after: On February 4, 2016, the reporting person was granted an option to purchase 130,000 shares of common stock. The option vests only upon achievement of a performance-based milestone. The performance criteria were met on January 30, 2017, resulting in vesting of the option. Upon achievement of the milestone, fifty percent of the shares immediately vest with the remaining shares vesting over the 24 month period following the vesting commencement date, subject to the reporting person's continuous service to Regulus. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 17:02 UTC | Regulus Therapeutics Inc. RGLS · Entity 78034 | GrantStock Option (Right to Buy) · Derivative | 186,640 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0001209191-16-145418 · doc4.xml · derivative · entry 1 GRINT PAUL C · CIK 0001236548 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,640 Underlying: Common Stock · 186,640 shares Expires 2026-10-04 F1 · derivative.exercise_date: 25% of the shares vest on October 5, 2017 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on October 5, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.